ACTU (Actuate Therapeutics) Ending Cash Position: $4.43 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.05
View Full Analysis

What is Actuate Therapeutics Ending Cash Position?

Actuate Therapeutics ACTU +6.06% 14 Ending Cash Position is $4.43 Mil as of Jun. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $4.43 Mil.

Actuate Therapeutics's quarterly Ending Cash Position declined from Dec. 2025 ($13.16 Mil) to Mar. 2026 ($8.13 Mil) and declined from Mar. 2026 ($8.13 Mil) to Jun. 2026 ($4.43 Mil).

Actuate Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($2.96 Mil) to Dec. 2024 ($8.64 Mil) and increased from Dec. 2024 ($8.64 Mil) to Dec. 2025 ($13.16 Mil).

Actuate Therapeutics Ending Cash Position Related Terms

Actuate Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Ending Cash Position Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
20.45 2.96 8.64 13.16

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.49 16.93 13.16 8.13 4.43
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Actuate Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=8.641+4.518
=13.16

Actuate Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.134+-3.708
=4.43

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $4.43 Mil mean?
Actuate Therapeutics (ACTU) has a Ending Cash Position of $4.43 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Ending Cash Position too high?
Actuate Therapeutics' current Ending Cash Position is $4.43 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Ending Cash Position compare to KYNB and IGC?
Actuate Therapeutics' Ending Cash Position of $4.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Ending Cash Position is $4.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Ending Cash Position of $4.43 Mil. The current Ending Cash Position is $4.43 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Ending Cash Position is $4.43 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.05
Price